<DOC>
	<DOC>NCT01381094</DOC>
	<brief_summary>The purpose of this study is to evaluate the dose response (efficacy), safety, and tolerability of orally administered AKB-6548 in pre-dialysis subjects with anemia with repeat dosing for 42 days.</brief_summary>
	<brief_title>42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Key 18 to 79 years of age, inclusive Chronic Kidney Disease (eGFR &lt;60 mL/min), not yet on dialysis Hemoglobin (Hgb) ≤ 10.5 g/dL TSAT ≥ 20% Ferritin ≥ 50 ng/mL Key BMI &gt;42 Red blood cell transfusion within 12 weeks Androgen therapy within the previous 21 days prior to study dosing Therapy with any approved or experimental erythropoiesis stimulating agent (ESA) within the 11 weeks prior to the Screening visit Subjects meeting the criteria of ESA resistance within the previous 4 months Individual doses of intravenous iron of greater than 250 mg within the past 21 days AST or ALT &gt;1.8x ULN Alkaline phosphatase &gt;2x ULN Total bilirubin &gt;1.5x ULN Uncontrolled hypertension New York Heart Association Class III or IV congestive heart failure Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>